Nurix Therapeutics, Inc. 4

Nurix Therapeutics Chief Legal Officer Christine Ring had several RSU vestings into common stock and a non-discretionary sale of 3,847 shares solely to cover taxes on July 30, 2026.

On July 30, 2026, Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring had multiple RSU-related transactions: three RSU tranches vested and were settled into 3,750, 2,858, and 3,572 shares of common stock respectively, and a separate sale of 3,847 shares of common stock occurred at a weighted average price of $23.3828 per share, solely to cover tax withholding obligations under a mandatory sell-to-cover arrangement. The RSU conversions were reported at a transaction price of $0, reflecting their nature as equity compensation rather than open-market purchases, and the issuer’s footnote clarifies that the sale was non-discretionary and executed within a price range of $23.00 to $23.90. Following these transactions, Ring’s directly owned common stock increased to 19,912 shares and she retained 39,303 RSUs outstanding that will continue to vest quarterly over three-year schedules, with future delivery of common stock conditioned on continued service to the company.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817199-26-000026

Alert Tier

5